|Admission to AIM||from 7 November 2018 as YGEN
from 4 July 2014 to 6 November 2018 as NIPT
|AIM symbol||YGEN (formerly NIPT)|
|Number of shares in issue||
598,999,688 (Date last updated 8 May 2019)
|% of shares not in public hands||
21% (Date last updated 8 May 2019)
|Significant Shareholders with more than 3%:||
(Date last updated 16 August 2019)
|The company is listed on the AIM market of the London Stock Exchange, and is subject to the UK City Code on Takeovers and Mergers.|
Dr Bill Chang holds options over 300,000 new ordinary shares, exercisable at 10.0p, and options over 400,000 new ordinary shares, exercisable at 7.75p. There are no other options, warrants or any other instruments held by significant shareholders.
Life Technologies Limited holds warrants over 20,325,204 new ordinary shares exercisable at 24.6p, warrants over 17,094,018 new ordinary shares exercisable at 11.7p, and warrants over 16,913,319 new ordinary shares exercisable at 11.8p.
Life Technologies Limited holds 41,356,165 ordinary shares which are subject to a lock-in deed until 17 February 2022. Subsequent to the acquisition of Delta Diagnostics (UK) Ltd (trading as Elucigene Diagnostics) completed on 25 April 2019, the former shareholders of Elucigene are subject to a lock-in deed until 24 April 2020. There are no other restrictions on the transfer of shares.